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Abstract
Head and neck squamous cell carcinomas (HNSCCs) are an aggressive, genetically complex and difﬁcult to treat group
of cancers. In lieu of truly effective targeted therapies, surgery and radiotherapy represent the primary treatment
options for most patients. But these treatments are associated with signiﬁcant morbidity and a reduction in quality of
life. Resistance to both radiotherapy and the only available targeted therapy, and subsequent relapse are common.
Research has therefore focussed on identifying biomarkers to stratify patients into clinically meaningful groups and to
develop more effective targeted therapies. However, as we are now discovering, the poor response to therapy and
aggressive nature of HNSCCs is not only affected by the complex alterations in intracellular signalling pathways but is
also heavily inﬂuenced by the behaviour of the extracellular microenvironment. The HNSCC tumour landscape is an
environment permissive of these tumours’ aggressive nature, fostered by the actions of the immune system, the
response to tumour hypoxia and the inﬂuence of the microbiome. Solving these challenges now rests on expanding
our knowledge of these areas, in parallel with a greater understanding of the molecular biology of HNSCC subtypes.
This update aims to build on our earlier 2014 review by bringing up to date our understanding of the molecular
biology of HNSCCs and provide insights into areas of ongoing research and perspectives for the future.
Facts
● The heterogeneous nature of HNSCC at the
molecular level has hindered both the identiﬁcation
of speciﬁc targets and development of targeted
therapeutics for this group of tumours.
● Advances in strategies in dissecting the features of
the HNSCC genome, transcriptome and
metabolome have revealed new altered targets. But
this has not yet resulted in clinical improvements in
the management of these cancers.
● Current treatment strategies are very toxic,
highlighting the need for treatment stratiﬁcation
using validated biomarkers to improve treatment
outcome and reduce toxicity and cost of HNSCC
treatment.
● Radiotherapy resistance remains a major cause of
HNSCC poor survival rates. Understanding the
underlying molecular mechanism of RT resistance
should signiﬁcantly impact patient survival
outcomes, but requires a multidisciplinary approach
combining imaging and molecular proﬁling.
● EGFR inhibitors, the only approved targeted drugs,
have limited efﬁcacy with the mechanisms of
inherent and acquired resistance remaining
unresolved.
● There has been a signiﬁcant increase in the
incidence of HPV-positive HNSCC, a subgroup with
more favourable prognosis. Strategies for treatment
de-escalation to reduce toxicity are urgently
required.
● New, tailorable treatments such as immunotherapy
have become highly valuable in the treatment of
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HNSCC. However, the importance of both the
tumour microenvironment and the role of tumour
immunity in pathogenesis and treatment response
needs further understanding.
● A possible relationship between the oral microbiome
and HNSCC has been reported, warranting further
research into the inﬂuence of the oral microbiome
on subsequent development of HNSCC.
Open questions
● How can HNSCC therapies, alone or in combination
(radiotherapy, chemotherapy, targeted drugs and
immunotherapy) be made more effective, to achieve
a good prognosis while minimising undesirable
treatment effects?
● For individuals with HPV-linked HNSCC, is it safe
and effective to use less aggressive treatment than
the usual highly toxic therapies?
● How can advances in precision medicine (and
identiﬁcation of biomarkers) help clinicians to
personalise treatment and predict outcomes, based
on the patient’s unique biochemistry and genetic
proﬁle?
● Can the relationship between tumour and
microenvironment (including the input of the
immune system and inﬂuence of the microbiome)
help us either treat, stratify patients or prevent
oncogenesis?
● To what extent is the HNSCC epigenome
contributing to evolution of the tumour? Will the
epigenome be the next-generation pharmacological
target for HNSCC?
Introduction
Head and neck squamous cell carcinomas (HNSCCs)
are the sixth most common malignancy worldwide,
accounting for over 500,000 new cases annually. Long-
term tobacco use, consumption of alcohol and infection
with high-risk types of Human Papilloma Virus (HPV) are
considered the main oncogenic drivers1,2. Treatment
involves surgical eradication, radiotherapy (RT) and che-
motherapy (CT). All modalities severely reduce quality of
life, and are largely ineffective. Most of the developments
towards understanding this disease have occurred in the
past few decades, but have fallen short of clinically
meaningful discoveries (Fig. 1). Efforts to improve treat-
ment efﬁcacy have been largely without success,
Fig. 1 Timeline of the molecular characterisation and therapeutic innovations in head and neck cancers, and future perspectives.
Interestingly, the major advances in our understanding of HNSCCs have only been made in the past 20–30 years. Also, some major discoveries
concerning the molecular characterisation of HNSCCs have been made almost 20 years after similar discoveries in other cancers. For example, where
HPV was proven unequivocally to cause cervical cancers around 1983, the same discovery was not made for HNSCCs until around the year 2000. It is
not so hard to understand therefore why therapeutic options for HNSCCs are so far behind, when our understanding of the molecular biology of
these diseases only began to develop over the past 2–3 decades. Dates are not exact, and the details presented are by no means exhaustive10–22
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highlighting an urgent need for more effective therapies,
alongside clinically relevant biomarkers to stratify patients
and improve treatment outcomes.
HNSCCs have a high rate of genetic heterogeneity3,
resulting in loss-of-function mutations in tumour-
suppressor genes such as p53 and p16INK4a, and activa-
tion of oncogenes, such as the epidermal growth factor
receptor (EGFR)4 and PIK3CA5. Until the recent FDA
approval of immunotherapies, Cetuximab, a monoclonal
antibody (mAb) targeting EGFR, has been the only tar-
geted drug approved for both HPV-positive and -negative
subtypes6. However, Cetuximab, and other therapies
designed to target EGFR, has limited efﬁcacy7 (Fig. 2).
In the absence of targeted therapies, radiotherapy
remains the main treatment modality for HNSCC, and
preferable for organ preservation8. HPV-positive patients
respond better to RT, a trait not fully understood. The use
of HPV as a biomarker for dose de-escalation has been
considered, but the value of this approach has not been
proven and concerns of under-treating these patients have
taken precedence9.
The efﬁcacy of RT is also substantially constrained by
the presence of tumour hypoxia. Hypoxia is a biomarker
of an aggressive phenotype, with higher rates of metastasis
and recurrence10. Again, a full molecular understanding
of this condition in HNSCC is lacking.
HNSCC subtypes are clinically, histologically and
molecularly distinct. Yet, these diseases are treated uni-
formly, and with limited success. Despite research efforts,
survival rates are at a deadlock. The lack of biomarkers for
personalised treatment suggests an urgent need for better
understanding of the intricate molecular biology of
HNSCC, alongside an understanding of
tumour–microenvironment interactions. This review will
Fig. 2 The genetic alterations in HPV-negative HNSCCs. EGFR, MET and NOTCH alterations promotes proliferation, migration and cellular survival
via signalling through the RAS/RAF/ERK, PI3K and JAK/STAT pathways, all of which are regularly dysregulated in HNSCC. Disruption of the p53
pathway also leads to high levels of genomic instability. Green boxes show possible therapeutic agents either approved (*) or under investigation for
clinical use in HNSCC. Information about the percentage of HNSCC cases showing either mutations or overexpression of the pathway as a whole
shown in red boxes, where this data are available. Note, though activation of the JAK/Stat pathway is regularly seen in HNSCC, no mutations have yet
been found1–9
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explore the current knowledge of HNSCC biology and
highlights areas of ongoing research towards improving
treatment outcomes.
The genetic landscape in HNSCC and its clinical
implications
The TP53/RB pathway
TP53 is a tumour-suppressor gene encoding a tran-
scription factor11 with roles in maintaining genomic sta-
bility, cell cycle, DNA repair, apoptosis and
senescence12,13. p53 is a major cellular stress sensor for
DNA damage or oncogene activation14–16. Over 80% of
HPV-negative HNSCCs have p53 mutations resulting in
the loss of function17,18. Mutations in TP53 occur early in
carcinogenesis, and are mostly associated with HPV-
negative cases, due to degradation of p53 by the HPV E6
oncoprotein19. In both subtypes, p53 mutations are
associated with poor overall survival, therapy resistance
and increased rate of recurrence17. In response to DNA
damage, p53 is regulated in a MDM2-dependent man-
ner20 and activated by cell cycle checkpoint kinases CHK1
and CHK2 resulting in cell-cycle arrest and apoptosis12.
Ampliﬁcation or overexpression of another p53 family
member, TP63, is observed in around 80% of HNSCCs21–23.
Of the two major isoforms produced by TP63 (TAp63 and
ΔNp63), ΔNp63 plays a major role in HNSCC pathogenesis,
regulating key pathways, including cell survival and renewal,
senescence suppression (by suppressing p16/INK4A) and
growth factor signalling24–26. Recent evidence indicates that
ΔNp63 inﬂuences the HNSCC metabolic microenviron-
ment via a transcriptional programme involving HAS3 and
HYAL genes, and the signalling of hyaluronic acid via
CD44, activating pro-proliferative and pro-survival path-
ways in HNSCC27. Another p53 family member, p73, and
its isoform TAp73 can indirectly inﬂuence growth arrest or
apoptosis by regulating p53 target genes. Despite the
retained DNA-binding activity of the other isoform ΔNp73,
it cannot transactivate p53 reporter genes28. In HNSCC,
TAp73 has been shown to suppress EGFR transcription and
induce cell death in EGFR-overexpressing cell lines28. In
cancers with mutant p53, proinﬂammatory cytokine TNF-
α-induced c-REL/ΔNp63α interactions, inactivate tumour
suppressor TAp73 function, promoting TNF-α resistance
and survival. c-REL depletion enhanced TAp73 promoter
interaction and expression of genes mediating growth arrest
and apoptosis29. However, while ampliﬁcation of P63 is
frequent in HNSCC and the consequent oncogenic func-
tion of ΔNp63 has been sufﬁciently understood, the extent
of p73 contributions to the disease needs further
investigation.
The retinoblastoma tumour suppressor (RB) regulates
cell-cycle progression at the restriction point between
early and late G1. As with TP53, mutations in the RB
pathway are an early alteration in HNSCC carcinogenesis.
The combined mutations of p53 and RB pathways result
in unlimited replication potential of cancer cells30. In
HPV-positive cancers, binding of viral protein E7 to pRb
results in degradation leading to E2F release and uncon-
trolled cellular proliferation30,31.
Several strategies for p53-targeted therapies have been
developed, such as adenoviral p53 gene therapy or use of
small molecules to restore TP53 function or disrupt
inactivation of wild-type p53. But, these have not proved
effective in clinical trials32. Other small molecules tar-
geting p53 for reactivation of p53 are in early-stage
investigations. COTI-2 (a derivative of thiosemicarba-
zones) showed activity in refolding mutant p53 and
restoring wild-type p53 function. A clinical trial
(NCT02433626) will soon test efﬁcacy of COTI-2 in
HNSCC33.
NOTCH pathway
A 2015 genomic analysis by the Cancer Genome Atlas
(TCGA) showed inactivating mutations in NOTCH1-3 to
be present in 17% of HPV-positive and 26% of HPV-
negative HNSCCs17. These aberrations predominantly
occur in NOTCH1 and include mis-sense mutations in
functional regions, non-sense mutations resulting in
truncated proteins and frameshift insertions or dele-
tions34. A recent HNSCC cohort study revealed poor
prognosis in NOTCH1 mutation cases, where direct
downstream targets HES1 and HEY1 were over-
expressed35,36. NOTCH1 signalling can contribute to the
maintenance of cancer stem cell traits responsible for
recurrence and metastasis through Wnt signalling37. The
crosstalk between Notch and Wnt signalling has been
reported in different types of cancers38. Loss of Notch
signalling was shown to increase transcriptional activity of
a β-catenin-responsive reporter construct in colon cancer
stem and progenitor cells39. In HNSCC, concurrent
NOTCH1 and FAT1 inactivating mutations drives carci-
nogenesis by activating β-catenin17. Importantly, loss of
Notch signalling was found to promote tumorigenesis in
HNSCC by upregulating ΔNp63, but the precise
mechanisms of Notch-ΔNp63 regulation remain to be
elucidated. Interestingly, Notch signalling in keratinocytes
could be impaired by ΔNp63 expression, suggesting a
reciprocal process between Notch and p63 in the
epidermis34.
The data from genomic and functional studies in the
lung, bladder and oesophagus support a tumour-
suppressor role for Notch signalling in epithelial SCCs
tumorigenesis40. Moreover, several in vivo models provide
results consistent with sequencing data from patient
samples that support a tumour-suppressive role of Notch.
However, in vitro studies using HNSCC cell lines
demonstrated that increased activity of Notch signalling is
required for maintaining malignant behaviour41. It is
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essential to functionally validate the role of Notch sig-
nalling in HNSCC using robust in vivo models, as in vitro
studies are unlikely to represent patient disease develop-
ment. Collectively, whether NOTCH mutations are acti-
vating or inactivating in HNSCC remains debatable42,43. It
may be that different types of mutations occur in different
subtypes of HNSCC35. This therefore must be carefully
considered when taking inhibitors or activators of this
pathway into clinical trials44,45.
PI3K/Akt/mTOR pathway
Recent molecular characterisation showed that in
HNSCC, PI3K/Akt/mTOR seems to be the most fre-
quently deregulated pathway. In HNSCC, the PI3KCA
gene harbours mutations at a rate of ~16%30. PI3Ks are a
class of enzymes vital for cellular growth, differentiation
and survival, activated by RTKs, such as EGFR. Other
members of the pathway include the mTOR complexes
(mTORC1 and mTORC2), and Akt. mTORC2 is essential
for Akt phosphorylation and activation of other signalling
molecules of the PI3K pathway, including SGK146.
Clinical trials have assessed the value of targeting this
pathway with drugs, including rapamycin, everolimus and
temsirolimus with encouraging outcomes47. Emergence of
resistance to mTOR inhibitors has been encountered in
HNSCC, though the mechanisms behind this resistance
are still being investigated48. In one such example, a
possible feedback loop between Akt and ERK/MAPK
signalling by mTOR inhibition was found to act as a
survival mechanism in tumour cells. Co-targeting mTOR
and EGFR, thus inhibiting upstream activation of the Akt
and ERK signalling pathway, has been suggested to
overcome this resistance49.
Epidermal growth factor receptor (EGFR) pathway
The epidermal growth factor receptor (EGFR, HER1 or
ErbB1) belongs to the HER/ErbB family of receptor tyr-
osine kinases (RTKs), which also includes HER2-4. EGFR
is overexpressed in 80–90% of HNSCC cases and corre-
lates with poor prognosis and treatment outcomes50.
EGFR signalling is a complicated and multidimensional
network, involving many individual players and overlap
with other pathways. As such, the potential for ther-
apeutic targeting of EGFR signalling is vast, representing
both a daunting challenge and tantalising opportunity for
HNSCC research.
EGFR is a transmembrane receptor with tyrosine kinase
activity51. Ligand binding triggers homo- or hetero-
dimerisation with other HER members and subsequent
phosphorylation of tyrosine residues, activating down-
stream signalling cascades. These pathways control pro-
liferation, differentiation, survival, angiogenesis, invasion
and metastasis in cancer52. EGFR can also translocate to
the nucleus where it may function as a transcription
factor. This translocation has been found to be triggered
by ionising radiation, resulting in radiotherapy resis-
tance53. EGFR has also been shown to interact with other
receptors, such as Axl, enhancing oncogenic potential54.
Targeting EGFR can be achieved either by blocking the
ligand-binding domain using monoclonal antibodies
(mAbs), or by inhibiting the activity of the tyrosine kinase
domain using small-molecule tyrosine kinase inhibitors
(TKIs). Cetuximab, a chimeric monoclonal antibody with
high speciﬁcity and afﬁnity to EGFR, remains the only
approved targeted therapy for HNSCC in combination
with RT/CT7,55,56. Despite high rates of EGFR over-
expression,Cetuximab has shown limited efﬁcacy in
HNSCC. This may be due to aberrations in other HER
family members and their ligands, and/or activation of
other downstream signalling components57,58.
The mechanisms behind inherent and acquired resis-
tance toCetuximab remain unsolved59. Several new tar-
geted therapies have been developed to target EGFR or its
signalling partners. So far, these have shown only modest
improvements in progression-free survival (PFS), and
none have been approved for treatment in HNSCC (see
Table 1).
Small TKIs of EGFR have been ineffective in HNSCC
although some early results from trials with combination
therapies have shown promise. Erlotinib, for example,
demonstrated modest improvements in PFS when used in
combination with an anti VEGF antibody (Bevacizumab)
in recurrent/metastatic (R/M)-HNSCC60. However, when
used for locally advanced (LA)-HNSCC in combination
with cisplatin and radiotherapy, the study group demon-
strated no improvements in disease progression. Afatinib,
a pan-HER TKI, has also been shown to have positive
anti-tumour activity comparable with Cetuximab61,62. In a
study comparing Afatinib to methotrexate, it was noted
that patients who experienced improvements in disease
outcomes had EGFR ampliﬁcation, low HER3, no
expression of p16 and high PTEN63, highlighting the
importance of identiﬁcation of biomarkers in patients
who show favourable response.
MET pathway
One proposed mechanism for resistance to EGFR-
targeted therapies is upregulation or activation of other
RTKs, such as c-MET (hepatocyte growth factor recep-
tor). C-MET encodes mesenchymal–epithelial transition
factor associated with increased migration, invasion and
metastasis in cancer64. C-MET mutations are reportedly
rare in HNSCC (2–13%), while gain in MET copy number
and overexpression of its ligand hepatocyte growth factor
(HGF) is common in HNSCCs65. The roles of HGF/c-
MET in HNSCC invasion and metastasis have been
investigated in many studies. C-MET has been found
overexpressed in lymph node metastasis, and HGF has
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been shown to promote anoikis resistance in HNSCC, an
essential step for nodal metastasis66. In patients, over-
expression is associated with worse prognosis and lower
overall survival67.
EGFR and c-MET share common downstream path-
ways, including the RAS-RAF-MAPK and PI3K-AKT-
mTOR pathways. Therefore, the MET-HGF axis could
represent a valuable therapeutic target in HNSCC, of
particular relevance to patients with resistance to EGFR-
targeted therapies64. Studies on dual blockade of EGFR
and c-MET have reported promising anti-tumor activity
of combined treatment67. Co-targeting both receptors has
demonstrated ability to sensitise cells to EGFR-targeted
therapies68. Capmatinib (INC-280) is a c-MET inhibitor
with anti-tumour activity in mouse models. A phase I trial
assessing Capmatinib safety in advanced solid tumours
(NCT01324479) is completed and awaiting results69.
Ficlatuzumab, a mAB that targets the HGF/c-MET axis, is
also being tested in clinical trials for HNSCC in combi-
nation with Cetuximab in R/M-HNSCC (NCT02277197).
Promising results from pre-clinical models of HNSCC
showed inhibition of proliferation, migration, invasion
and EMT70.
JAK/STAT pathway
In both HPV-positive and HPV-negative HNSCCs,
aberrant regulation of the signal transducer and activator
of transcription (STAT) family has been reported. Upre-
gulation of STAT3 and its gene targets is thought to
contribute to the malignant behaviour of HNSCCs,
resistance to chemo/radiotherapy and EGFR-targeted
therapy71–74.
STAT3 signalling is considered immunosuppressive and
may protect cancer cells from recognition and lysis by
cytotoxic T lymphocytes, achieved by triggering production
of cytokines, including IL-6, IL-10, VEGF and TGF- β175.
STAT3 is activated in response to upstream signals of the
IL-6 cytokine receptor family, RTKs such as EGFR, VEGFR,
Jenus-activated kinases (JAK) and Src family kinases
(SFK)76. Following activation, nuclear phospho-STAT3
promotes expression of target genes including pro-survival
factors, such as cyclin D1, survivin and Bcl-xL71.
In the context of STAT3 targeting, Ruxolitinib is an
approved JAK inhibitor for myeloﬁbrosis. A clinical trial
currently in the recruitment phase aims to test efﬁcacy of
Ruxolitinib in HNSCC (NCT03153982). AZD9150, a
synthetic anti-sense oligonucleotide molecule targeting
STAT3 by inhibiting mRNA translation, has demon-
strated anti-tumour activity in xenograft models. It is
currently being tested in clinical trials of metastatic
HNSCC cases as a monotherapy or combined with
MED14736, an immunotherapy blocking the interaction
of PD-1 and PD-L1 (NCT02499328)77.
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RAS/RAF/MAPK pathway
The mitogen-activated protein kinase (MAPK) pathway
regulates expression of proteins involved in cell pro-
liferation, differentiation, apoptosis, angiogenesis, inva-
sion and metastasis78. It comprises four sub-pathways of
which the Erk1/2 pathway has received most attention in
HNSSCC. Upon binding of growth factors (such as EGF),
a signalling cascade results in activated Erk1/2 that dis-
sociates from the Ras-Raf-MEK-ERK1/2 complex and
phosphorylates a number of cytoskeletal proteins, kinases
and transcription factors, including NF-κB, AP-1, ETS-1
and c-Myc79. Mutations in the MAPK pathway have been
implicated in other cancers, however, in HNSCC muta-
tions only represent 4% of cases17,80. MEK inhibitors, such
as Trametinib, are currently approved for melanoma
treatment, and are being investigated in clinical trials for
HNSCC81.
HPV-associated HNSCC
HPV is a risk factor associated with 22% of orophar-
yngeal (OPSCC) and 47% of tonsillar squamous cell car-
cinomas (TSCC). The incidence of HPV-positive HNSCC
increased 225% from 1984 to 2004, and has now sur-
passed the incidence of HPV-induced cervical cancer5.
This increase is thought to be a consequence of changes
in sexual behaviour82. Of the 200 types of HPV viruses,
HPV-16 is the most common type found in HNSCCs
(90% of HPV-OPSCC), followed by HPV-18 (3%).
Clinically, HPV-positive patients often present with
small tumours, but with advanced nodal metastasis. The
epidemiological proﬁle for HPV-positive patients is
unique, with the majority of patients being young, white
and male9. Crucially, HPV-positive HNSCC patients
demonstrate favourable prognosis, with a 28% reduced
risk of death and almost 50% reduced risk of local
recurrence when compared with HPV-negative patients83.
HPV-positive patients show improved response to radio-
therapy and chemotherapy84. Whether this is due to the
molecular pathogenesis, or related to age and better
overall health of patients remains unclear.
In contrast to HPV-derived cervical cancers, in HNSCC,
dysplastic lesions are rarely found before cancers are
diagnosed. The HPV virus is also not commonly found in
non-malignant tonsil tissue samples85. Evidence suggests
that the tonsillar crypt epithelium on its own might not be
permissive of the viral reproductive cycle. Despite this, the
microenvironment is such that some 47% of infections
within the tonsillar crypts can progress to cancer. Notably,
only 3.9% of HPV infections in the oral cavity lead to
cancer9.
Genetic alteration in HPV-derived HNSCC is primarily
characterised by inactivation of p53 and pRB by viral
proteins E6 and E7, respectively (Fig. 3). E5 is also
implicated in carcinogenesis through activation of
signalling pathways, involving EGFR, immune recognition
and regulation of apoptosis86. PI3K mutations are
observed in 30% of HPV-associated HNSCC87, based on
current genomic data, mutation hotspots of PIK3CA vary
between HPV-positive and negative tumours. Mutations
predominantly occur in the helical domain of the gene in
the HPV-positive subtype, whereas mutations occur
throughout the gene in HPV-negative tumours88. These
differences may have an impact on clinical outcomes to
PI3K/mTOR inhibitors, and even have predictive value48.
TCGA data demonstrates the presence of several other
genetic differences, including, loss of TRAF (a tumour-
suppressor gene implicated in anti-viral immunity
response) and aberrant activation of cell-cycle genes89.
The most frequently altered genes in HPV-negative
HNSCCs are often unaltered in HPV-positive HNSCCs.
However, the alteration of p53, p16INK4A and RB as a
result E6 and E7 in HPV-positive cases is functionally
similar5. A recent study using TCGA data, sought to
further classify HNSCC tumours based on HPV status
and TP53/CDKN2A mutation status. The results
demonstrated that genes involved in DNA mismatch
repair were upregulated in HPV-positive tumours, a
pathway implicated in the cytotoxicity of chemo/radio-
therapy90, thus providing a possible insight into the
improved response of these patients to radiotherapy91.
Currently, there are no subtype-speciﬁc treatment
regimens available9. Several trials have assessed de-
intensiﬁcation of treatment of HPV-positive cancers
using various methods, including reducing total dose of
radiation, RT as a monotherapy and replacing conven-
tional chemotherapy with targeted therapies. The results
of some phase III clinical trials aiming to assess efﬁcacy of
replacing platinum-based chemotherapy with Cetuximab
and radiotherapy, including RTOG 1016, TROG 12.01
and the De-ESCALaTE trial92–95, are published. These
trials report that EGFR inhibition by Cetuximab conferred
a reduction in overall survival and tumour control when
compared with cisplatin. The authors of the De-
ESCALaTE trial also recommend caution when con-
sidering reducing the dose of radiotherapy for HPV-
positive patients. Additional efforts have been made
towards the development of therapeutic HPV vaccines96.
Database analysis of head and neck squamous cell
carcinomas
Following the omics revolution, the amount of data
generated with the aim of uncovering biomarkers, net-
work motifs and susceptibility markers has soared. The
development of databases to the structure and sharing of
these data has been critical. See Sepiashvili et al. for
detailed biomarker data with respect to HNSCC97.
Both genomic and proteomic data can be accessed, with
databases such as the GEO omnibus98 and Array
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Express99 containing microarray data, DNA- and RNA-
sequencing, and DNA methylation studies (Table 2) and
The Human Protein Atlas containing results from tumour
tissue staining100,101. These databases have their own
merits and pitfalls. Whereas GEO and Array Express
comprehensively gather all species and cell types, the
Cancer Genome Atlas (TCGA) speciﬁcally focuses on
patient-derived samples and contains information about
genomic changes in different cancer types. For head and
neck, this includes 44 healthy and 504 cancer samples102.
TCGA comprises mRNA, miRNA and protein expression
data as well as DNA methylation status. The Leipzig
Health Atlas contains gene expression proﬁling and tar-
geted sequencing of 50 genes of 290 consecutively
recruited HNSCC patients103. For metabolic alterations
observed in HNSCC a variety of medium and small-scale
data sets have been generated as summarised by Shin
et al.104. Furthermore, a genomic information portal for
HNSCC cell systems has been set up, detailing clinical and
genomic information of 44 cell lines105.
The Danish Head and Neck Cancer group
(DAHANCA) established in 1976, was set up with the aim
Fig. 3 Aberrant signalling in HPV-positive HNSCC. HPV oncogenesis occurs mainly in the tonsillar crypt epithelium of the oropharynx. Upon HPV
infection, viral DNA is either integrated or exists in the cells in episomes. Regardless, this allows for transcription of viral oncoproteins E5, E6 and E7.
The main dysregulation attributed to carcinogenesis in HPV-positive cases stems from the inhibition of p53 by the E6 viral protein, and of Rb by E7.
This leads to entry into the cell cycle via release of E2F, and inhibition of p53-mediated cell death. It also results in the accumulation of p16, which
subsequently acts as a surrogate marker of HPV infection in HNSCC. Though previously considered a minor player, E5 has also been shown to activate
EGFR leading to further oncogenic potential. Amongst the signalling pathways shown to be activated in HPV-HNSCC, the PI3K pathway has been
found to be signiﬁcantly upregulated. This may in part be due to activation by ErbB family members, including both EGFR and Her31,7,23–26
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of generating guidelines for the treatment of HNSCCs
based on patient cases. To date, they have compiled data
from more than 33,000 patients containing variables
incorporating symptoms, aetiological factors, diagnostic
evaluation and involvement in clinical trials106. This
database is a valuable resource for longitudinal studies,
which have clear advantages over single case studies.
However, the accessibility of DAHANCA to the scientiﬁc
community is limited by the use of the Danish language in
all reports. The National Cancer Database (NCDB), based
in the USA, collects information submitted from hospitals
detailing the state of cancer care throughout the country.
Between 1990 and 2004, information of around 800,000
head and neck tumours were collected107.
In contrast to these large studies, some databases have
attempted to group all decentralised information into a
single source. One such database for head and neck
cancer is HNdb, which was established with the aim to
combine genomics, transcriptomics and proteomics data,
literature citations, and cross-references from external
databases. For this purpose, Henrique et al. established a
text mining procedure to identify genes in literature
related to HNSCC. Their database provides user-friendly
access to information on HNSCC-related genes and their
different biological data resources108. Overall, the large
amounts of data amassed so far offer a great foundation
for the identiﬁcation of possible biomarkers, to begin
working towards personalised medicine for HNSCC.
The microenvironmental landscape
Hypoxia in HNSCC
Hypoxia is a well-established cause of poor response to
treatment, metastasis and recurrence. It develops as a
result of progressive tumour growth leading to impair-
ment of oxygen supply within tumour tissues. This results
in the development of areas starved of oxygen30. Within
these regions, central areas (experiencing oxygen levels <
0.1% O2) will likely become necrotic. The cells within
regions of acute hypoxia (< 2% O2) that survive these
extreme conditions adapt a programme of gene expres-
sion leading to treatment resistance and metastasis109–111.
The hypoxic response is primarily mediated by the
heterodimeric hypoxia-inducible factors (HIF-1-3). Under
normal oxygen conditions, the HIFα subunits undergo
rapid degradation by the E3-Ubiquitin Ligase Von-
Hippel-Lindau protein (VHL). Under hypoxic condi-
tions, HIFα is stabilised and binds to HIFβ in the nucleus,
where the activated HIF complex binds to hypoxia
response elements (HREs), allowing for adaption of the
tumour. HREs are present in genes responsible for alter-
ing metabolism (CA9, GLUT1), EMT (Vimentin), extra-
cellular matrix remodelling (LOX, MMPs), angiogenesis
(VEGF), immune modulation and inﬂammation (TNFα,
IL1β)112–116.
The state of hypoxia is not clear-cut, with several
examples of stabilisation of HIFs in normoxic conditions.
mTOR has been shown to induce expression of HIF-1α in
tumour areas that are not signiﬁcantly hypoxic, and has
been attributed to various oncogenic mechanisms, such as
inactive p53 mutations, excessive accumulation of oxygen
radicals, RAS mutations, inactivation of PTEN and inef-
fective degradation of HIF-1α by mutations in VHL112.
Gain-of-function mutations in p53 have shown a syner-
gism with HIF signalling. A recent study in hypoxic
NSCLC found p53 mutations that regulate a selective
gene signature including extracellular matrix (ECM)
components, such as type VIIa1 collagen and laminin-γ2.
This study illustrated the impact of p53 mutants on the
microenvironment in co-operation with HIF-1 to pro-
mote cancer progression117,118. By considering the high
frequency of p53 mutations in HPV-negative HNSCC and
the hypoxia observed in these tumours, the co-operation
between p53 mutants and HIF-1 signalling might repre-
sent a meaningful avenue for clinical investigation.
Hypoxic tumours represent a distinct subtype of
HNSCCs with poor prognosis and treatment resistance.
Attempts have been made to make clinical use of this
information. Hypoxic modulation has been suggested to
revert the changes that occur in low oxygen and restore
sensitivity to treatment. Hyperbaric oxygen therapy is one
such method which aims to improve tumour oxygena-
tion119,120. Hypoxia-activated pro-drugs including
Table 2 Some examples of publicly available data from studies involving genomic proﬁling of HNSCC samples
Study by Type Array identiﬁer
Farah et al.126 microRNA proﬁling by array E-MTAB-6470
Hess et al.127 microRNA proﬁling by array E-MTAB-5198
Bossi et al.128 Transcription proﬁling by array E-GEOD-65021
Wood et al.129 RNA-seq of coding RNA E-GEOD-72536
Selvi et al.130 Transcription proﬁling by array E-GEOD-75029
Wichmann et al., Leipzig Head and Neck Group, 2015120 Transcription proﬁling by array https://www.health-atlas.de/en/
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Tirapazamine and Nimorazole are thought to act as
oxygen-mimetic radiosensitizers. The latter is now
included in the standard of care for Danish HNSCC
patients, following guidelines from DAHANCA110,121.
A trial using Nimorazole alongside RT for patients
with R/M-HNSCC is currently recruiting in the UK
(NIMRAD)122.
Targeting hypoxia therapeutically to overcome treat-
ment resistance needs accurate and reliable detection
methods. Several approaches including needle electrodes,
endogenous or exogenous hypoxia tissue markers and
hypoxia imaging have been tested, but have limitations.
Needle electrodes are an invasive method limited to
accessible tumours, albeit with demonstrable prognostic
value in HNSCC tumours123. To overcome these limita-
tions, endogenous hypoxia biomarkers have been identi-
ﬁed in patient tissues and serum, the most commonly
used being GLUT-1, CA9, VEGF and serological bio-
marker OPN124. Several hypoxia-speciﬁc gene signatures
(HGS) have been developed125–127, with evidence of HGS
having prognostic and predictive values. Notably, a 15-
gene HGS from human HNSCC xenografts has been
identiﬁed and further validated in a cohort of 302 HNSCC
patients with successful discrimination between low and
high hypoxic tumours127.
Positron emission tomography (PET)/computer tomo-
graphy (CT) using hypoxia-speciﬁc radiotracers, com-
bined with assessment of endogenous or exogenous
hypoxia markers could provide a reliable clinical method
for both detection and measurement of tumour hypoxia
during treatment126,128. In HNSCC, PET imaging using
the hypoxia radiotracer 18F-MISO has been investigated,
demonstrating successful identiﬁcation of HNSCC
patients who beneﬁted from addition of Tirapazamine
with prediction of recurrence after radiotherapy129.
Likewise, a recent study by Suh et al. combined hypoxia
imaging with PET/CT using 64Cu-ATSM and gene
expression of patient tumours to validate a HGS, linked to
prognosis126.
The immune-microenvironment in HNSCC
Immune evasion is considered a key hallmark of cancer,
generating an environment permissive of survival and
progression. HNSCCs are immune-suppressive, with the
ability to avoid recognition and clearance by immune
cells. This evasion of immunosurveillance is achieved by
alterations, including loss or downregulation of human
leucocyte antigens (HLAs) expression, impaired recogni-
tion of cancer cells by T cells and activation of MAPK,
STAT3 and β-catenin/Wnt signalling pathways130. The
HNSCC tumour microenvironment has also been shown
to have impaired function of tumour-inﬁltrating lym-
phocytes (TILs)131.
Both HPV-negative and HPV-positive tumours show
high levels CD8+ cytotoxic T cells and activated NK
cells132. However, these tumours still evade their cytotoxic
mechanisms. For clinical purposes, research is ongoing to
investigate efﬁcacy of enhancing immune cell targeting of
tumours. A potential method for this could be to exploit
the presence of tumour-associated neoantigens expressed
on cancer cells resulting from genetic reconﬁgurations133.
Adoptive immunotherapy, which involves administra-
tion of genetically modiﬁed T cells targeting speciﬁc
antigens expressed on the surface of tumour cells, is a
recent revolutionary advance in cancer immunotherapy.
The synthetic chimeric antigen receptor (CAR)-T cell
therapy has shown remarkable success in haematological
cancers134. An FDA-approved CD19-targeting CAR-T cell
therapy has demonstrated success in leukaemias and
lymphomas, encouraging the development of similar
therapies for solid tumours135. However, these therapies
face multiple challenges such as a need to identify speciﬁc
tumour-associated antigens that are overexpressed in
tumours, but not in normal tissues136. A recent ongoing
trial developed a pan-ErbB-targeted CAR-T cell therapy
for HNSCC (NCT01818323)137.
The momentous discovery that certain proteins act as
“immune checkpoints” by regulating the T-cell response
has spurred efforts to develop treatments to reverse this
effect and restore anti-tumour immune responses138,139.
In normal circumstances proteins including programmed
death protein (PD-1), its ligand (PD-L1) and cytotoxic T-
lymphocyte-associated protein 4 (CTLA-4), function to
prevent autoimmunity140,141. PD-L1 has been detected in
most human cancers and leads to anergy and apoptosis of
activated T cells and subsequent immune evasion of the
tumour cells142–145. These proteins are often over-
expressed and co-opt this protective mechanism to inhibit
immune activation. Immune checkpoint blockade thera-
pies have shown remarkable clinical success for some
cancers, including metastatic melanoma140,146,147. In
2016, anti-PD1 mAb Nivolumab was FDA-approved for
recurrent/metastatic HNSCC patients with progressive
disease or failure of platinum-based therapy. The approval
followed the promising results of the CheckMate 14 trial,
demonstrating a statistically signiﬁcant improvement in
OS and quality of life in patients treated with nivolu-
mab148. Pembrolizumab, another anti-PD1 mAb, was in
the same year approved in R/M-HNSCC treatment after
the positive results of the KEYNOTE-12 trial149. Studies
to approve these drugs as mono or combination therapies
for different cancer types is ongoing.
Cancer-associated ﬁbroblasts
Cancer-associated ﬁbroblasts (CAFs) are ﬁbroblast-like
cells associated with the tumour that develop an activated
phenotype, expressing markers such as α-smooth muscle
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actin (α-SMA) and ﬁbroblast activation protein (FAP)150.
These ﬁbroblasts, alongside inﬁltrating immune cells, can
resemble the architecture of a wounded tissue. However,
unlike wound ﬁbroblasts, CAFs are often resistant to cell
death mechanisms and remain activated151–153. Commu-
nication, through direct contact and secretion of signal-
ling molecules between CAFs and tumour cells is vital for
their function154. With perpetual activation of CAFs, the
tumour can beneﬁt from CAF secretion of proteins for
ECM remodelling155, growth factors152, cytokines, che-
mokines and recruitment of immune-suppressive cells156.
This environment supports tumour growth, migration,
invasion, angiogenesis, colonisation of distant tissues by
way of the CAF-supported “pre-metastatic niche” and
evasion of the immune system157–161. An additional
danger engendered by this stroma–tumour communica-
tion has been the reported changes in responsiveness to
cancer therapy161–163. This is particularly relevant in
HNSCC, as CAFs have been shown to regulate response
to Cetuximab164 and radiotherapy165,166. Research has
shown that these treatments in turn impact CAF
activation167,168.
A number of potential targeting strategies exist to block
CAF-mediated tumour support, including inhibition of
CAF cell-surface proteins (such as the anti-FAP antibody
Sibrotuzumab169), blocking CAF activation or by targeting
CAF-tumour signalling159. Tumour cells are also thought
to contribute to activation of CAFs via a transformation
process involving exosomes containing nucleic acids like
microRNAs170,171, chemokines and cytokines like TGFβ,
CXCL12 (CXC-Chemokine ligand 12 also known as
SDF1) and IL-6, as well as local stimuli like hypoxia and
oxidative stress154,156,172. Though research within this
ﬁeld with respect to HNSCC is somewhat under-
developed, many of these factors have independently been
implicated in its oncogenesis173–177. Recent work by Hersi
et al. showed that low expression of the tumour-
suppressive miR-9, which targets the CXCL12 receptor
CXCR4, was linked to aggressive behaviour of HNSCC
cells, counteracted by targeting of this interaction with
Plerixafor (a CXCR4 inhibitor)178. Likewise, IL-6, its
receptor and downstream JAK/STAT signalling have all
been strongly implicated in HNSCC prognosis71,179. A
recent study showed that IL-6 was responsible for both
promoting oncogenesis when secreted from CAFs and
CAF activation when secreted from tumour cells180.
Importantly, targeting some of these mechanisms, such
as the CXCL12-CXCR4 and IL-6 pathways, could result in
inhibition of both the tumour stroma and the tumour
itself. One challenge associated with targeting CAFs in the
HNSCC microenvironment relates to their heterogeneity.
Their biology is complex, and CAFs likely originate from a
number of different cell types181. In practice, this non-
uniform pool of cells has been difﬁcult to characterise
completely. One beneﬁt of CAFs is that they are geneti-
cally stable, unlike tumour cells, which may make long-
term treatment plans more viable159. As with much of
what has been reviewed herein, holistic approaches
involving combinations of immune therapy, conventional
therapy and CAF-targeted therapy may prove most useful
for future treatment.
The oral microbiome
Changes in the oral microbiome have been proposed to
contribute to oncogenesis in the 7–15% of oral cancer
cases, which cannot be explained by known risk fac-
tors182–184. The microbiome denotes the collective gen-
ome of complex communities of bacteria, archaea, viruses,
fungi and protists, each with crucial roles to play in sta-
bilising microbial diversity185,186. The clinical relevance of
the oral microbiome lies in the statistical association
between dysbiosis (often a result of poor oral health) and
the prevalence of many types of cancer187–189. Within the
multifarious environment of the human mouth, with its
mucosal surfaces and deep-tissue crevices, both healthy
and malignant sites contain distinct microbial
populations190,191.
Several bacterial species have been associated with oral
cancer. A potential biomarker signature has been sug-
gested for oral cancer and consists of the three bacterial
species Capnocytophaga gingivalis, Prevotella melanino-
genica and Streptococcus mitis. These bacteria are found
in 80% of OSCC cases, and the signature has demon-
strated a diagnostic sensitivity of 80% and a speciﬁcity of
82%192. Another three-fungal signature of Rhodotorula,
Geotrichum and Pneumocystis, as well as the micro-
sporidia Phialophora and Cladophialophora are speciﬁ-
cally seen in OCSCC183.
Risk factors for HNSCCs including tobacco and alcohol
consumption and HPV infection have been shown to
affect the oral microbiome193–196. A shift towards differ-
ent genera of bacteria has been associated with exposure
to these risk factors. Oral microbes have also been shown
to contribute to acetaldehyde (the carcinogenic meta-
bollite of ethanol) production, which can induce muta-
genesis, and hyperproliferation of the epithelium197.
Bacterial strains show signiﬁcant differences in their
ability to produce acetaldehyde, for instance, S. mitis
produces high amounts of acetaldehyde and has sig-
niﬁcant alcohol dehydrogenase activity198. Concurrently,
elevated levels of S. mitis have been detected in OSCC192.
Acetaldehyde and malondialdehyde production from
Streptococcus species such as Streptococcus gordonii
V2016 signiﬁcantly increased bacterial attachment to
keratinocytes, facilitated HPV infection by enhanced
expression of furin and resulted in malignant transfor-
mation of infected keratinocytes199. Oral Streptococcus
species and HPV seem to co-operate in order to infect and
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transform oral keratinocytes after exposure to alcohol.
Cleavage of the minor capsid protein L2 by furin is
required for HPV infection200,201. Since only a subset of
bacteria contains enzymes with furin-like activity, this
might contribute to HPV tissue tropism202.
The carcinogenic potential of several bacteria has been
demonstrated in vitro and in animal models184. Chronic
infection of P. gingivalis or F. nucleatum have been shown
to augment the IL-6-STAT3 inﬂammatory cascade and
promote HNSCC development203. Interactions between
periodontopathogenic bacteria and single-nucleotide
polymorphisms (SNPs) of Toll-like receptors (TLRs)
such as TLR2 and TLR4 have also been shown to inﬂu-
ence OSCC risk204–206. Virulent P. gingivalis strains can
induce expression of PD-L1 and PD-L2 receptors in
squamous carcinoma cells, mediated by the membrane
fraction of P. gingivalis207,208.
Particularly relevant for HNSCC and its treatment
options, some microbiota such as C. albicans and E. fae-
calis can activate EGFR signalling209–211. In addition, E.
faecalis can drive tumorigenesis by hydrogen peroxide-
mediated DNA damage, chromosomal instability and
mutagenesis211. The compositional and functional varia-
tions of oral microbiota have been associated with the
mutational changes in oral cancer. Yang et al. investigated
the oral microbiome composition of OSCC patients in
association with their mutational proﬁle and identiﬁed
three patient clusters, which varied in their bacterial
species richness and their relative abundance of Firmi-
cutes and Bacteroidetes212.
The clinical relevance of the microbiome is important as
treatments such as radiotherapy cause alterations in
healthy oral microﬂora, partially due to treatment-
induced xerostomia213–215. Ultimately these alterations
can result in exacerbation of mucositis and systemic
infections. Patients who have good oral care during cancer
therapy have better outcomes213. Different treatments in
oral cancer patients have distinct effects on microﬂora216.
Opportunistic pathogens such as staphylococci, enteric
rods and Candida sp. tend to increase in prevalence after
radiotherapy (IMRT) with or without chemotherapy217. C.
albicans was found in one or more sites in 54% of patients
who received radiotherapy in comparison with 15% of
controls188.
A new avenue for personalised treatment could involve
targeting the microbiome for therapeutic purposes with
microbial supplements, such as synbiotics (probiotics and
prebiotics), diet or microbial suppression strategies using
antibiotics218–223. Probiotics have the potential to protect
against cancer development in animal models, and some
probiotic strains diminish the incidence of postoperative
inﬂammation in cancer patients224–229. Importantly, most
commercial probiotic products are generally safe and can
improve the health of the host by modulating the
intestinal microbiota and immune response230. Therefore,
probiotic strains might be useful adjuvants for cancer
prevention and/or treatment231. Lactobacillus brevis CD2
lozenges have been shown to reduce the severity and
incidence of radio/chemotherapy-induced mucositis in
HNSCC patients, thereby increasing the rate of anticancer
treatment completion232,233.
In brief, the emerging ﬁelds of microbiomics and
metagenomics will help to identify the presence of
HNSCC-speciﬁc microbes and help us understand234 the
development of accurate and cost-effective diagnostic and
therapeutic strategies.
Conclusion
The heterogeneous nature of HNSCCs has hindered the
identiﬁcation of speciﬁc targets for the development of
targeted therapies. Over the past 30 years we have
developed a better understanding of the genomic, pro-
teomic, microbiomic and metabolomic alterations in
HNSCCs. This knowledge is helping to move us closer to
personalised therapy, where each subtype can be treated
as a separate disease. The signiﬁcant problems associated
with high toxicities as well as resistance to current
treatments, and low quality of life for patients, make these
efforts particularly crucial. Since our last clinical update in
20144, our understanding of these diseases has broadened
to not only consider the endogenous alterations as key
contributors to oncogenesis but also to consider the
microenvironmental factors that build an environment
permissive of these oncogenic mechanisms. How the
integration of microenvironmental factors and genetic
backgrounds reshapes the HNSCC epigenome is largely
unclear and represents one of the new priorities in the
ﬁeld. It is likely that interdisciplinary approaches seeking
to link the genetic and microenvironmental biology of
HNSCC will allow us to better treat HNSCC in the future.
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